News

Novartis announced that the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the prevention of vaso-occlusive crises (VOCs)…
Read More...

Almac Sciences, a member of the Almac Group, has expanded its technology capabilities within its Active Pharmaceutical Ingredients (API) services & chemical development portfolio…
Read More...

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on novel, disease-modifying therapies for neurodegenerative diseases announced its plans to initiate a…
Read More...

Aphena Pharma Solutions Inc. has announced the expansion of its blister packaging capacity with the purchase of a PharmaWorks TF2 blister packaging line with in-line cartoning…
Read More...

Ascentage Pharma announced that Unity Biotechnology has selected one of Ascentage's compounds as its lead development candidate in its ophthalmology pipeline to advance into further…
Read More...

Generex Biotechnology Corporation announced that the company has completed the acquisition of 51% of Olaregen Therapeutix Inc., a New York based regenerative medicine company that is…
Read More...

CANbridge Pharmaceuticals and WuXi Biologics jointly announced an expansion of their rare disease partnership to enable CANbridge to discover, develop and commercialize four additional…
Read More...

Velabs Therapeutics, specializing in the fast generation of functional therapeutic antibodies, announced that it has entered into a collaboration agreement with BioMed X Innovation…
Read More...

Regeneron Pharmaceuticals and Sanofi have restructured their global Immuno-oncology Discovery and Development Agreement for new immuno-oncology cancer treatments. The 2015 Agreement was…
Read More...

The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval…
Read More...

CytoReason announced that it has entered into a collaboration agreement with Pfizer that will leverage CytoReason’s cell-centered models of the immune system. CytoReason will receive…
Read More...

GE Healthcare and Vanderbilt University Medical Center (VUMC) announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will…
Read More...

AmpliPhi Biosciences Corporation and C3J Therapeutics announced that the companies have entered into a definitive agreement under which a wholly owned subsidiary of AmpliPhi will merge…
Read More...

Recipharm announces that it will initiate a process to explore the discontinuance of operations at its solid dose manufacturing facility in Ashton-under-Lyne, UK. The decision to…
Read More...

Merck KGaA, Darmstadt, Germany announced that through its wholly owned subsidiary, Ares Trading, it has evolved its agreement with Intrexon Corporation for the development of Chimeric…
Read More...

Eli Lilly and Company and Aduro Biotech, Inc. announced a research collaboration and exclusive license agreement for Aduro's cGAS-STING Pathway Inhibitor program for the research and…
Read More...

Gilead Sciences and Agenus Inc. announced the companies have entered into an immuno-oncology (I-O) partnership focused on the development and commercialization of up to five novel…
Read More...

Novartis announced an offer to acquire CellforCure from LFB. CellforCure, a French company, is one of the first and largest contract development and manufacturing organizations (CDMO)…
Read More...

Novartis announced that Susanne Schaffert, Ph.D., currently President, Advanced Accelerator Applications (AAA), a Novartis company, has been appointed CEO Novartis Oncology. She will…
Read More...

TOKYO & Astellas Pharma Inc. and Pfizer Inc. announced that the Phase 3 ARCHES trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic…
Read More...